Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by targeting molecular alterations regardless of tumour ...

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. TNBC is ...

Not all tumour cells the same Tumours aren't made up of just one cell type – they're a mix of different cells that grow and respond to treatment in different ways. This diversity, or heterogeneity, ...

Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial. This is an ASCO Meeting ...

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer. Until now, all available treatments, including immunotherapy — which involves ...

In recognition of Breast Cancer Awareness Month, join us for a live webinar to uncover the complexity of tumor biology and the surprising resilience of normal tissue. This event will feature two ...

Canada's colorectal cancer (CRC) screening programs, which are run at the provincial or territorial level, meet the International Agency for Research on Cancer's (IARC) criteria for access to ...